Trial Profile
Phase IIA Trial of Rosiglitazone (Avandia) for Oral Leukoplakia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Rosiglitazone (Primary)
- Indications Leucoplakia; Mouth neoplasm
- Focus Biomarker; Therapeutic Use
- 24 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Sep 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
- 24 Jun 2008 Additional trial identifier MDA2005-0485 reported by ClinicalTrials.gov.